JP2018522053A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522053A5
JP2018522053A5 JP2018506137A JP2018506137A JP2018522053A5 JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5 JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018506137 A JP2018506137 A JP 2018506137A JP 2018522053 A5 JP2018522053 A5 JP 2018522053A5
Authority
JP
Japan
Prior art keywords
combination
composition
tlr4 agonist
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522053A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/053290 external-priority patent/WO2017021792A1/en
Publication of JP2018522053A publication Critical patent/JP2018522053A/ja
Publication of JP2018522053A5 publication Critical patent/JP2018522053A5/ja
Pending legal-status Critical Current

Links

JP2018506137A 2015-08-06 2016-06-03 Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用 Pending JP2018522053A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201912P 2015-08-06 2015-08-06
US62/201,912 2015-08-06
PCT/IB2016/053290 WO2017021792A1 (en) 2015-08-06 2016-06-03 Tlr4 agonists and compositions thereof and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2018522053A JP2018522053A (ja) 2018-08-09
JP2018522053A5 true JP2018522053A5 (enExample) 2019-07-04

Family

ID=56121139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506137A Pending JP2018522053A (ja) 2015-08-06 2016-06-03 Tlr4アゴニストおよびその組成物ならびに癌の処置におけるそれらの使用

Country Status (10)

Country Link
US (1) US10765690B2 (enExample)
EP (1) EP3331565A1 (enExample)
JP (1) JP2018522053A (enExample)
KR (1) KR20180032642A (enExample)
CN (1) CN108136024A (enExample)
AU (1) AU2016303387B2 (enExample)
BR (1) BR112018002520A2 (enExample)
CA (1) CA2994790A1 (enExample)
RU (1) RU2018107930A (enExample)
WO (1) WO2017021792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
PL3752182T3 (pl) 2018-02-12 2024-11-25 Inimmune Corporation Ligandy receptorów toll-podobnych
WO2020007760A1 (en) * 2018-07-03 2020-01-09 Glaxosmithkline Intellectual Property Development Limited Tlr4 compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions or formulations, methods of preparation, treatment or uses
WO2020031087A1 (en) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
TW202233200A (zh) * 2020-11-11 2022-09-01 日商第一三共股份有限公司 新穎胺基烷基葡萄胺糖苷4-磷酸衍生物
CN117018195B (zh) * 2023-08-04 2024-05-21 中国人民解放军海军军医大学 小分子化合物或组合在制备启动肝脏原位再生药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO2001090129A2 (en) 2000-05-19 2001-11-29 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
AU8100101A (en) 2000-08-04 2002-02-18 Corixa Corp New immunoeffector compounds
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CA2748038A1 (en) * 2008-12-23 2010-07-01 Glaxosmithkline Biologicals S.A. Method for inducing a trif-bias
EP3192811A1 (en) * 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EP3711768A1 (en) * 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment

Similar Documents

Publication Publication Date Title
JP2019521180A5 (enExample)
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
CA2999253C (en) Heterocyclic compounds and uses thereof
JP2013503174A5 (enExample)
NZ739902A (en) Multiligand agent for drug delivery
JP2019508440A5 (enExample)
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
GEP20237470B (en) Magl inhibitors
WO2016098054A9 (en) Processes for preparing oxathiazin-like compounds
EA201370103A1 (ru) Соединения и композиции для лечения рака
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
HRP20150530T1 (hr) Spojevi korisni za inhibiranje chk1
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
JP2013541586A5 (enExample)
GEAP202115056A (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
WO2018083635A3 (en) Tricyclic heterocyclic derivatives and uses thereof
RU2019105574A (ru) Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
WO2015193517A3 (en) Liquid pharmaceutical composition comprising pemetrexed
CO6341557A2 (es) Derivados nitrogenados de la pancratistatina
JOP20210079A1 (ar) التركيبة القائمة على السيكلوديكسترين لمثبط bcl-2